- GW Pharmaceuticals' Sativex has been approved in Sweden for the treatment of spasticity due to Multiple Sclerosis.

GW said Sweden's Medical Products Agency had granted regulatory approval for Sativex (Delta-9-Tetrahydro-cannabinol and Cannabidiol) oromucosal spray as a treatment of moderate to severe spasticity due to MS in patients who have not responded adequately to other anti-spasticity medicationi.

Sativex is a first in class endocannabinoid system modulator and is currently available in the UK, Germany, Spain and Denmark.

GW says evidence generated from clinical trials shows that Sativex has a positive impact on spasticity in multiple sclerosis, while alleviating associated symptoms including pain, bladder or sleep disturbance.

By relieving the symptoms of MS, Sativex can improve patients' quality of life and allow them greater independence in performing their daily activities.

The launch of Sativex in Sweden is expected to take place during the first half of 2012 following completion of the national pricing and reimbursement process.

Sativex will be marketed in Sweden by GW's marketing partner, Almirall.

Story provided by